{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:18:16Z","timestamp":1791908296492,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T00:00:00Z","timestamp":1703289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Americas"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.lana.2023.100667","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T12:47:27Z","timestamp":1704545247000},"page":"100667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Disease-modifying drugs, multiple sclerosis and infection-related healthcare use in British Columbia, Canada: a\u00a0population-based study"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4249-4665","authenticated-orcid":false,"given":"Jonas","family":"Graf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8381-5253","authenticated-orcid":false,"given":"Huah Shin","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinshan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 MA.","family":"Wijnands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charity","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Fisk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Ann","family":"Marrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5804-2535","authenticated-orcid":false,"given":"Helen","family":"Tremlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lana.2023.100667_bib1","article-title":"Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis","volume":"4","author":"Filippini","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.lana.2023.100667_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy174","article-title":"Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management","volume":"5","author":"Epstein","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10.1016\/j.lana.2023.100667_bib3","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1177\/13524585211069068","article-title":"The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review","volume":"28","author":"Tur","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.lana.2023.100667_bib4","first-page":"2033","article-title":"Epidemiology of multiple sclerosis: results from a large observational study in the UK","volume":"262","author":"Jick","year":"2015","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.lana.2023.100667_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000166602","article-title":"Monthly ambient sunlight, infections and relapse rates in multiple sclerosis","volume":"31","author":"Tremlett","year":"2008","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.lana.2023.100667_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102462","article-title":"Urinary tract infection in patients with multiple sclerosis: an overview","volume":"46","author":"Medeiros Junior","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.lana.2023.100667_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2023.107851","article-title":"Common comorbid and secondary conditions leading to hospitalization in multiple sclerosis patients in the United States","volume":"232","author":"Asemota","year":"2023","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.lana.2023.100667_bib8","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1177\/1352458516681198","article-title":"Infection-related health care utilization among people with and without multiple sclerosis","volume":"23","author":"Wijnands","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.lana.2023.100667_bib9","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/ene.12130","article-title":"Hospital admission due to infections in multiple sclerosis patients","volume":"20","author":"Montgomery","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.lana.2023.100667_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.msard.2017.10.019","article-title":"Common comorbidities and survival in MS: risk for stroke, type 1 diabetes and infections","volume":"19","author":"Murtonen","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.lana.2023.100667_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102420","article-title":"Infections in patients with multiple sclerosis: a national cohort study in Sweden","volume":"45","author":"Castelo-Branco","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.lana.2023.100667_bib12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lana.2023.100667_bib13","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/jnnp-2017-317493","article-title":"Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study","volume":"89","author":"Wijnands","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.lana.2023.100667_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101982","article-title":"Infections in patients diagnosed with multiple sclerosis: a multi-database study","volume":"41","author":"Persson","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.lana.2023.100667_bib15","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1212\/WNL.0000000000002471","article-title":"The challenge of comorbidity in clinical trials for multiple sclerosis","volume":"86","author":"Marrie","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.lana.2023.100667_bib16","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1212\/WNL.0000000000002474","article-title":"Recommendations for observational studies of comorbidity in multiple sclerosis","volume":"86","author":"Marrie","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.lana.2023.100667_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.yfrne.2018.07.001","article-title":"A\u00a0case for gender-based approach to multiple sclerosis therapeutics","volume":"50","author":"Houtchens","year":"2018","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.lana.2023.100667_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420969016","article-title":"Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials","volume":"13","author":"Zhang","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.lana.2023.100667_bib19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/WCO.0000000000000701","article-title":"Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis","volume":"32","author":"Schweitzer","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.lana.2023.100667_bib21","series-title":"Medical services plan (MSP) payment information file. V2. Population data BC [publisher]","year":"2017"},{"key":"10.1016\/j.lana.2023.100667_bib22","series-title":"Discharge Abstract database (hospital separations). V2","year":"2017"},{"key":"10.1016\/j.lana.2023.100667_bib23","series-title":"PharmaNet. V2","year":"2017"},{"key":"10.1016\/j.lana.2023.100667_bib24","series-title":"Postal code OM conversion file (PCCF), reference guide. Catalogue no. 92-154-G","author":"Statistics Canada","year":"2017"},{"key":"10.1016\/j.lana.2023.100667_bib25","series-title":"Consolidation file (MSP registration & Premium billing). V2","year":"2017"},{"key":"10.1016\/j.lana.2023.100667_bib26","series-title":"Vital Statistics deaths. V2","year":"2017"},{"key":"10.1016\/j.lana.2023.100667_bib27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1212\/WNL.0b013e3181cf6ec0","article-title":"The rising prevalence and changing age distribution of multiple sclerosis in Manitoba","volume":"74","author":"Marrie","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.lana.2023.100667_bib28","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1177\/13524585221078497","article-title":"Emergency department use by persons with MS: a population-based descriptive study with a focus on infection-related visits","volume":"28","author":"Graf","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.lana.2023.100667_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.794075","article-title":"Disease-modifying drug uptake and health service use in the ageing MS population","volume":"12","author":"Ng","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.lana.2023.100667_bib30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1017\/cjn.2017.301","article-title":"Establishing the incidence and prevalence of multiple sclerosis in saskatchewan","volume":"45","author":"Al-Sakran","year":"2018","journal-title":"Can J Neurol Sci"},{"issue":"5","key":"10.1016\/j.lana.2023.100667_bib31","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200005","article-title":"Disease-modifying drugs for multiple sclerosis and association with survival","volume":"9","author":"Ng","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.lana.2023.100667_bib32","first-page":"3","article-title":"The disease-modifying drugs for multiple sclerosis and subsequent health service use: a population-based study. 036","volume":"27","author":"Ng","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.lana.2023.100667_bib33","first-page":"2352","article-title":"High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010)","volume":"262","author":"Kingwell","year":"2015","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.lana.2023.100667_bib34","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1017\/S0317167100015961","article-title":"The incidence and prevalence of multiple sclerosis in Nova Scotia, Canada","volume":"40","author":"Marrie","year":"2013","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"10.1016\/j.lana.2023.100667_bib35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14737175.2021.1847085","article-title":"Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting","volume":"21","author":"Ng","year":"2021","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.lana.2023.100667_bib36","author":"WHO"},{"issue":"4","key":"10.1016\/j.lana.2023.100667_bib37","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1177\/13524585211063403","article-title":"Disease-modifying drugs for multiple sclerosis and subsequent health service use","volume":"28","author":"Ng","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.lana.2023.100667_bib38","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events","volume":"62","author":"Lin","year":"2000","journal-title":"J\u00a0Roy Stat Soc B"},{"key":"10.1016\/j.lana.2023.100667_bib50","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/jama.2020.1267","article-title":"Why test for proportional hazards?","volume":"323","author":"Stensrud","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.lana.2023.100667_bib39","series-title":"Sample size calculations in clinical research","author":"Chow","year":"2017"},{"key":"10.1016\/j.lana.2023.100667_bib40","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1212\/WNL.0000000000002543","article-title":"Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis","volume":"86","author":"Zhang","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.lana.2023.100667_bib41","series-title":"Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus","first-page":"281","author":"Muller","year":"2005"},{"key":"10.1016\/j.lana.2023.100667_bib42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2377-13-16","article-title":"Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance","volume":"13","author":"Marrie","year":"2013","journal-title":"BMC Neurol"},{"key":"10.1016\/j.lana.2023.100667_bib43","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.lana.2023.100667_bib44","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","article-title":"Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)","volume":"91","author":"Butzkueven","year":"2020","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.lana.2023.100667_bib45","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1177\/1352458520964778","article-title":"Age-related adverse events of disease-modifying treatments for multiple sclerosis: a meta-regression","volume":"27","author":"Prosperini","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.lana.2023.100667_bib46","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/jac\/dkw054","article-title":"Gender differences in antibiotic prescribing in the community: a systematic review and meta-analysis","volume":"71","author":"Schr\u00f6der","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.lana.2023.100667_bib47","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/ana.21102","article-title":"New natural history of interferon-beta-treated relapsing multiple sclerosis","volume":"61","author":"Trojano","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lana.2023.100667_bib48","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ana.21185","article-title":"Interferon-beta treatment and the natural history of relapsing-remitting multiple sclerosis","volume":"63","author":"Koch","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lana.2023.100667_bib49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/ana.21352","article-title":"Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis","volume":"64","author":"Renoux","year":"2008","journal-title":"Ann Neurol"}],"container-title":["The Lancet Regional Health - Americas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X23002417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X23002417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:56:00Z","timestamp":1762642560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667193X23002417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":49,"alternative-id":["S2667193X23002417"],"URL":"https:\/\/doi.org\/10.1016\/j.lana.2023.100667","relation":{},"ISSN":["2667-193X"],"issn-type":[{"value":"2667-193X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease-modifying drugs, multiple sclerosis and infection-related healthcare use in British Columbia, Canada: a\u00a0population-based study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Americas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lana.2023.100667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100667"}}